- Home
- TSAT vs RZLT Comparison
TSAT vs RZLT Comparison
Compare TSAT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- RZLT
- Stock Information
- Founded
- TSAT 1969
- RZLT 2010
- Country
- TSAT Canada
- RZLT United States
- Employees
- TSAT N/A
- RZLT N/A
- Industry
- TSAT Metal Fabrications
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- TSAT Industrials
- RZLT Health Care
- Exchange
- TSAT Nasdaq
- RZLT Nasdaq
- Market Cap
- TSAT 515.2M
- RZLT 713.4M
- IPO Year
- TSAT 1996
- RZLT N/A
- Fundamental
- Price
- TSAT $33.66
- RZLT $8.96
- Analyst Decision
- TSAT
- RZLT Strong Buy
- Analyst Count
- TSAT 0
- RZLT 6
- Target Price
- TSAT N/A
- RZLT $14.50
- AVG Volume (30 Days)
- TSAT 144.7K
- RZLT 1.4M
- Earning Date
- TSAT 11-13-2025
- RZLT 11-06-2025
- Dividend Yield
- TSAT N/A
- RZLT N/A
- EPS Growth
- TSAT N/A
- RZLT N/A
- EPS
- TSAT N/A
- RZLT N/A
- Revenue
- TSAT $358,754,564.00
- RZLT N/A
- Revenue This Year
- TSAT N/A
- RZLT N/A
- Revenue Next Year
- TSAT N/A
- RZLT N/A
- P/E Ratio
- TSAT N/A
- RZLT N/A
- Revenue Growth
- TSAT N/A
- RZLT N/A
- 52 Week Low
- TSAT $10.11
- RZLT $2.22
- 52 Week High
- TSAT $36.85
- RZLT $9.72
- Technical
- Relative Strength Index (RSI)
- TSAT 63.89
- RZLT 57.91
- Support Level
- TSAT $31.12
- RZLT $7.80
- Resistance Level
- TSAT $35.80
- RZLT $9.22
- Average True Range (ATR)
- TSAT 2.48
- RZLT 0.52
- MACD
- TSAT 0.03
- RZLT -0.07
- Stochastic Oscillator
- TSAT 70.63
- RZLT 60.05
About TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.